295 related articles for article (PubMed ID: 16324129)
21. Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release.
Abosch A; Kapur S; Lang AE; Hussey D; Sime E; Miyasaki J; Houle S; Lozano AM
Neurosurgery; 2003 Nov; 53(5):1095-102; discussion 1102-5. PubMed ID: 14580276
[TBL] [Abstract][Full Text] [Related]
22. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
[TBL] [Abstract][Full Text] [Related]
23. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
[TBL] [Abstract][Full Text] [Related]
24. Striatal dopamine release during unrewarded motor task in human volunteers.
Badgaiyan RD; Fischman AJ; Alpert NM
Neuroreport; 2003 Aug; 14(11):1421-4. PubMed ID: 12960756
[TBL] [Abstract][Full Text] [Related]
25. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study.
Politis M; Piccini P; Pavese N; Koh SB; Brooks DJ
Exp Neurol; 2008 Nov; 214(1):112-6. PubMed ID: 18723016
[TBL] [Abstract][Full Text] [Related]
26. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
[TBL] [Abstract][Full Text] [Related]
27. In vivo presynaptic and postsynaptic striatal dopamine functions in idiopathic normal pressure hydrocephalus.
Ouchi Y; Nakayama T; Kanno T; Yoshikawa E; Shinke T; Torizuka T
J Cereb Blood Flow Metab; 2007 Apr; 27(4):803-10. PubMed ID: 16926840
[TBL] [Abstract][Full Text] [Related]
28. Dopamine release in human ventral striatum and expectation of reward.
de la Fuente-Fernández R; Phillips AG; Zamburlini M; Sossi V; Calne DB; Ruth TJ; Stoessl AJ
Behav Brain Res; 2002 Nov; 136(2):359-63. PubMed ID: 12429397
[TBL] [Abstract][Full Text] [Related]
29. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET.
Yagi S; Yoshikawa E; Futatsubashi M; Yokokura M; Yoshihara Y; Torizuka T; Ouchi Y
J Nucl Med; 2010 Aug; 51(8):1250-7. PubMed ID: 20660377
[TBL] [Abstract][Full Text] [Related]
30. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease.
Rinne JO; Laihinen A; Någren K; Bergman J; Solin O; Haaparanta M; Ruotsalainen U; Rinne UK
J Neurosci Res; 1990 Dec; 27(4):494-9. PubMed ID: 1981915
[TBL] [Abstract][Full Text] [Related]
31. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men.
Boileau I; Dagher A; Leyton M; Gunn RN; Baker GB; Diksic M; Benkelfat C
Arch Gen Psychiatry; 2006 Dec; 63(12):1386-95. PubMed ID: 17146013
[TBL] [Abstract][Full Text] [Related]
32. Imaging in Parkinson's disease: the role of monoamines in behavior.
Brooks DJ; Piccini P
Biol Psychiatry; 2006 May; 59(10):908-18. PubMed ID: 16581032
[TBL] [Abstract][Full Text] [Related]
33. New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET - [(11)C]raclopride study.
Moresco RM; Volonte MA; Messa C; Gobbo C; Galli L; Carpinelli A; Rizzo G; Panzacchi A; Franceschi M; Fazio F
J Neural Transm (Vienna); 2002 Oct; 109(10):1265-74. PubMed ID: 12373560
[TBL] [Abstract][Full Text] [Related]
34. Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study.
Goerendt IK; Messa C; Lawrence AD; Grasby PM; Piccini P; Brooks DJ;
Brain; 2003 Feb; 126(Pt 2):312-25. PubMed ID: 12538400
[TBL] [Abstract][Full Text] [Related]
35. Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study.
Meyer JH; McNeely HE; Sagrati S; Boovariwala A; Martin K; Verhoeff NP; Wilson AA; Houle S
Am J Psychiatry; 2006 Sep; 163(9):1594-602. PubMed ID: 16946186
[TBL] [Abstract][Full Text] [Related]
36. Endogenous dopamine release after pharmacological challenges in Parkinson's disease.
Piccini P; Pavese N; Brooks DJ
Ann Neurol; 2003 May; 53(5):647-53. PubMed ID: 12730999
[TBL] [Abstract][Full Text] [Related]
37. Striatal dopamine transmission in healthy humans during a passive monetary reward task.
Hakyemez HS; Dagher A; Smith SD; Zald DH
Neuroimage; 2008 Feb; 39(4):2058-65. PubMed ID: 18063390
[TBL] [Abstract][Full Text] [Related]
38. Mapping the amphetamine-evoked changes in [11C]raclopride binding in living rat using small animal PET: modulation by MAO-inhibition.
Pedersen K; Simonsen M; Østergaard SD; Munk OL; Rosa-Neto P; Olsen AK; Jensen SB; Møller A; Cumming P
Neuroimage; 2007 Mar; 35(1):38-46. PubMed ID: 17223363
[TBL] [Abstract][Full Text] [Related]
39. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
40. A PET study with [11-C]raclopride in Parkinson's disease: preliminary results on the effect of amantadine on the dopaminergic system.
Volonté MA; Moresco RM; Gobbo C; Messa C; Carpinelli A; Rizzo G; Comi G; Fazio F
Neurol Sci; 2001 Feb; 22(1):107-8. PubMed ID: 11487182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
